<DOC>
	<DOCNO>NCT02220933</DOCNO>
	<brief_summary>The purpose study demonstrate superiority MD1003 placebo disability patient suffer progressive multiple sclerosis especially gait impairment .</brief_summary>
	<brief_title>Effect MD1003 Spinal Progressive Multiple Sclerosis</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<criteria>Diagnosis criterion secondary primary progressive MS clinical evidence spastic paraparesis fulfilling revise McDonald criterion ( 2010 ) Lublin criterion ( 1996 ) Progression EDSS past two year least 1 point EDSS 4.5 5.5 least 0.5 point EDSS 6 7 EDSS score 4.5 7 ( measure away relapse confirm 6 month ) Informed consent prior study procedure Patient age 1875 year Any general chronic handicap disease MS Intensive physical therapy program within 3 month prior inclusion Impossibility perform TW25 test New treatment introduce less 3 month prior inclusion less 1 month Fampridine Pregnancy woman childbearing potential without contraception Evidence inflammatory activity disease define `` clinical evidence relapse year inclusion evidence new gadoliniumenhanced lesion brain MRI perform year inclusion . ''</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Multiple Sclerosis</keyword>
	<keyword>MS</keyword>
	<keyword>EDSS</keyword>
</DOC>